EMERYVILLE, Calif., Nov. 18, 2021 /PRNewswire/ -- Dynavax Technologies Corporation /zigman2/quotes/203017054/composite DVAX +6.42% , a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on Tuesday, November 30, at 2:40 p. m. E.T.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations . A replay of the webcast will be available for 30 days following the live event.
About Dynavax Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn .
Contacts:
Nicole Arndt, Investor Relations and Corporate Communications
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
SOURCE Dynavax Technologies
COMTEX_397220854/2454/2021-11-18T16:10:13
Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.
Copyright (C) 2021 PR Newswire. All rights reserved
Add to watchlist
DVAX
